VBI Vaccines

VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of infectious disease and immuno-oncology vaccines. The firm focuses on the prevention and treatment of hepatitis B through its product pipeline, Sci-B-Vac and VBI-2601. It also develops an enveloped virus-like particle (eVLP) platform technology, which allows the development of eVLP vaccines that closely mimic the target virus to elicit a potent immune response. The company was founded on April 9, 1965 and is headquartered in Cambridge, MA.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

VBI Vaccines, Inc. (VBIV) closed the most recent trading day at $3.76, making no change from the previous trading session.

VBI Vaccines, Inc. (VBIV) Flat As Market Sinks: What You Should Know

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc.

VBI Vaccines Announces Biomarker Data From VBI-1901 Phase 1/2a Study in Recurrent GBM Presented at ESMO Virtual Congress 2020

The biotech will present additional data for one of its pipeline candidates later this week.

Why VBI Vaccines Stock Jumped Today

VBI Vaccines to Present Additional Biomarker Data from VBI-1901 Phase 1/2a Study in Recurrent GBM in an E-Poster at ESMO Virtual Congress 2020

VBI Vaccines, Inc. (VBIV) closed at $3.12 in the latest trading session, marking a +0.65% move from the prior day.

VBI Vaccines, Inc. (VBIV) Outpaces Stock Market Gains: What You Should Know

VBI Vaccines Presents Phase 3 Sci-B-Vac® Data at EASL 2020

Investors who are looking for promising coronavirus vaccine stocks should keep an eye out for this emerging biotech.

Why Is Everyone Talking About VBI Vaccines Stock?

VBI Vaccines (VBIV) selects two coronavirus vaccine candidates for clinical-stage development based on encouraging pre-clinical data.

VBI Vaccines Up on Coronavirus Vaccine Candidates Selection

Pre-clinical results indicate that both are effective in only single doses.

VBI Vaccines Picks 2 Coronavirus Vaccine Candidates for Further Development

Shares of VBI Vaccines Inc (NASDAQ: VBIV) are moving strongly to the upside Thursday.

VBI Vaccines Surges On Preclinical Coronavirus Update, Analyst Upgrade

Investors are fired up about an analyst's enthusiastic upgrade of the biotech stock.

Why VBI Vaccines Stock Is Skyrocketing Today

 VBI Vaccines Announces Preclinical Coronavirus Program Data and Selection of Clinical Candidates with Potential as One-Dose Vaccines

The potential rewards with this biotech stock are high, but so are the risks.

Is VBI Vaccines Stock a Buy?

VBI Vaccines Announces Multiple Phase 3 Sci-B-Vac® Abstracts Accepted for Oral and Poster Presentations at EASL 2020

If you're hoping this biotech will win big with its coronavirus vaccine candidate, you may be looking in the wrong place.

Is It Too Late to Buy VBI Vaccines Shares?

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Therapure Biomanufacturing, a division of Therapure Biopharma Inc., announced today the signing of an agreement with VBI Vaccines Inc.

Therapure Biomanufacturing Signs Manufacturing Deal With VBI Vaccines for Coronavirus Vaccine Candidates

OTTAWA, Ontario & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--Variation Biotechnologies Inc.

VBI Vaccines Awarded Up to CAD$56 Million Contribution from Canadian Government to Accelerate Coronavirus Vaccine Development

VBI Vaccines Announces Second Quarter 2020 Financial Results and Provides Corporate Update

Moderna

One biotech keeps making headlines, the other's much quieter. But both have been big gainers, and both have strong potential opportunities.

Better Coronavirus Stock: Moderna vs. VBI Vaccines

A sell-off that began last week continues.

Why VBI Vaccines Stock Is Sinking Today

VBI Vaccine (VBIV) will provide financial updates when it releases second-quarter 2020 results.

VBI Vaccines (VBIV) to Report Q2 Earnings: What's in Store

VBI Vaccines: COVID-19 Narrative Boosts Hepatitis B Vaccine Prospects

Altimmune

Dynavax Technologies

NantKwest

Novavax

My COVID-19 Vaccine Report Card

Vaxart

There's more to these small biotechs than just their coronavirus vaccine programs.

Better Coronavirus Stock: VBI Vaccines or Vaxart?

VBI Vaccines (VBIV) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

VBI Vaccines (VBIV) in Focus: Stock Moves 8.3% Higher

News for VBI Vaccines Stock (VBIV)